Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6265806 | 0.90 | ADAM17 (0.43) | LIPEADAMTS5NPC1DRD4KMT2A | |
| SCHEMBL6501862 | 0.89 | BACE1 (0.42) | LIPENPC1KMT2AMEN1 | |
| SCHEMBL6260380 | 0.87 | RORC (0.37) | ATMKMT2AMEN1 | |
| SCHEMBL6498530 | 0.87 | ADAMTS5 (0.44) | LIPEADAMTS5PARP10PARP14NPC1 | |
| SCHEMBL6263120 | 0.86 | ALDH1A1 (0.39) | KMT2AMEN1 | |
| SCHEMBL6075935 | 0.85 | KMT2A (0.40) | KMT2AMEN1 | |
| SCHEMBL6490738 | 0.85 | ADAMTS5 (0.46) | LIPEADAMTS5PARP10PARP14NPC1 | |
| SCHEMBL6076026 | 0.84 | ALDH1A1 (0.40) | PARP10DRD4CHRM4KMT2AMEN1 | |
| SCHEMBL6490761 | 0.83 | OPRL1 (0.43) | DRD4KMT2AMEN1 | |
| SCHEMBL6264475 | 0.83 | RORC (0.38) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115633-B2 | Central nervous system disorders; Alzheimer's diseases; eating disorders | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-03 | — | — | US | disclosed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040029917-A1 | Benzosuberonylpiperdine compounds as analgesics | GLAXOSMITHKLINE S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | LIPE 3326/4885ADAMTS5 4882/4885PARP10 4165/4885 |
| US-20040029917-A1 | Benzosuberonylpiperdine compounds as analgesics | OPRK1, OPRL1, OPRM1 | LIPE 2699/4885ADAMTS5 4834/4885PARP10 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.